These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 16710544)

  • 21. Public health-oriented intellectual property and trade policies in Africa and the regional mechanism under Trade-Related Aspects of Intellectual Property Rights amendment.
    Adekola TA
    Public Health; 2019 Aug; 173():1-4. PubMed ID: 31203136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The trends and constructive ambiguity in international agreements on intellectual property and pharmaceutical affairs: Implications for domestic legislations in low- and middle-income countries.
    Son KB; Lee TJ
    Glob Public Health; 2018 Sep; 13(9):1169-1178. PubMed ID: 28585477
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ethics of intellectual property rights in an era of globalization.
    Shah AK; Warsh J; Kesselheim AS
    J Law Med Ethics; 2013; 41(4):841-51, Table of Contents. PubMed ID: 24446942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intellectual property rights and right of access to medicines].
    Velásquez G
    Med Trop (Mars); 2006 Dec; 66(6):526-8. PubMed ID: 17286013
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Implications of bilateral free trade agreements on access to medicines.
    Correa CM
    Bull World Health Organ; 2006 May; 84(5):399-404. PubMed ID: 16710551
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring risks of investor claims brought forth after the TRIPS waiver for COVID-19.
    Kulkarni SM; Kaur V
    Pharm Pat Anal; 2022 Nov; 11(6):165-174. PubMed ID: 36314462
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
    Townsend B; Gleeson D; Lopert R
    Asia Pac J Public Health; 2016 Nov; 28(8):682-693. PubMed ID: 27920239
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TRIPS and the global pharmaceutical market.
    Barton JH
    Health Aff (Millwood); 2004; 23(3):146-54. PubMed ID: 15160812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRIPS to Where? A Narrative Review of the Empirical Literature on Intellectual Property Licensing Models to Promote Global Diffusion of Essential Medicines.
    Mermelstein S; Stevens H
    Pharmaceutics; 2021 Dec; 14(1):. PubMed ID: 35056944
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Global health and Brazilian foreign policy: the negotiations on innovation and intellectual property.
    Lima JHDS
    Cien Saude Colet; 2017 Jul; 22(7):2213-2221. PubMed ID: 28724003
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poverty, health & intellectual property rights with special reference to India.
    Satyanarayana K; Srivastava S
    Indian J Med Res; 2007 Oct; 126(4):390-406. PubMed ID: 18032814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. WTO approves TRIPS amendment on importing under compulsory licensing.
    Herget G
    HIV AIDS Policy Law Rev; 2006 Apr; 11(1):23-4. PubMed ID: 16805011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of the trade-related aspects of intellectual property rights (TRIPS) agreement on India as a supplier of generic antiretrovirals.
    Babovic S; Wasan KM
    J Pharm Sci; 2011 Mar; 100(3):816-21. PubMed ID: 20740678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.
    Kohler J; Wong A; Tailor L
    Health Hum Rights; 2022 Dec; 24(2):159-175. PubMed ID: 36579316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patent implications in the pharmaceutical industry: Are static high prices leading to dynamic innovations?
    Pandey E; Paul SB
    Int J Risk Saf Med; 2019; 30(3):179-192. PubMed ID: 31450515
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Analyzing the impact of trade and investment agreements on pharmaceutical policy: provisions, pathways and potential impacts.
    Gleeson D; Lexchin J; Labonté R; Townsend B; Gagnon MA; Kohler J; Forman L; Shadlen KC
    Global Health; 2019 Nov; 15(Suppl 1):78. PubMed ID: 31775767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Improving global access to new vaccines: intellectual property, technology transfer, and regulatory pathways].
    Crager SE
    Rev Panam Salud Publica; 2015 Jan; 37(1):59-68. PubMed ID: 25791189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.
    Chattu VK; Singh B; Kaur J; Jakovljevic M
    Biomed Res Int; 2021; 2021():6658070. PubMed ID: 34485525
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Canada and access to medicines in developing countries: intellectual property rights first.
    Lexchin J
    Global Health; 2013 Sep; 9():42. PubMed ID: 24007595
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soaring antiretroviral prices, TRIPS and TRIPS flexibilities: a burning issue for antiretroviral treatment scale-up in developing countries.
    Orsi F; d'almeida C
    Curr Opin HIV AIDS; 2010 May; 5(3):237-41. PubMed ID: 20539080
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.